Keywords: declining, drug, launches, europe, drives, imperative, sustained
Declining drug launches in Europe drives imperative for sustained lifecycle pricing
Article | 22 July 2002
Only 10 new products were launched by the top 16 pharmaceuticalcompanies in Europe in 2001 (see table below), a drop for the second ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
